Breaking News Instant updates and real-time market news.

CVS

CVS Health

$79.23

-0.69 (-0.86%)

, AET

AET

13:17
11/15/18
11/15
13:17
11/15/18
13:17

California regulator approves CVS's acquisition of Aetna

The California Department of Managed Health Care Director Shelley Rouillard approved CVS Health Corporation's (CVS) acquisition of Aetna (AET). Per the DMHC's approval, CVS and Aetna agree to not increase premiums as a result of acquisition costs, and keep premium rate increases to a minimum. The plans also agree to invest nearly $240M in California's health care delivery system. As part of the DMHC's conditions, CVS and Aetna confirmed the sale of Aetna's Medicare Part D Individual Prescription Drug business to WellCare (WCG) in compliance with the conditional approval by the U.S. Department of Justice. Additionally, until the divestiture is completed, CVS and Aetna will ensure Aetna's Medicare Part D Individual Prescription Drug business in California continues to be a viable and competitive plan for 2019. Reference Link

CVS

CVS Health

$79.23

-0.69 (-0.86%)

AET

AET

WCG

WellCare

$246.88

-4.14 (-1.65%)

CVS CVS Health
$79.23

-0.69 (-0.86%)

11/07/18
MSCO
11/07/18
NO CHANGE
Target $100
MSCO
Overweight
CVS Health price target raised to $100 from $80 at Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser said he believes the combination of CVS (CVS) and Aetna (AET) has the potential to transform the delivery of care as he introduced pro forma estimates for the combined company. He noted the wide range of consensus estimates, with EPS ranges from $6.63-$8.21 for 2019 and $7.45-$9.05 for 2020, while telling investors that his own pro-forma EPS forecasts are for $7.57 in 2019 and $8.30 in 2020. In setting up a valuation framework for the combined company, Goldwasser raised his price target on CVS shares to $100 from $80 and keeps an Overweight rating on the stock.
11/08/18
LEER
11/08/18
NO CHANGE
Target $95
LEER
Outperform
CVS Health price target raised to $95 from $85 at Leerink
Leerink analyst David Larsen raised his price target for CVS Health (CVS) to $95 from $85 following quarterly results. The analyst is encouraged that the deal with Aetna (AET) appears to be ready to close in the near-term, which he believes will be a positive catalyst for the stock. Larsen also likes how the PBM selling season seems to be progressing well, better than he had expected, and also likes how CVS seems to be re-focusing on the Retail "Streamline" efforts, which will hopefully result in net savings in 2019. The analyst reiterates an Outperform rating on CVS shares.
11/09/18
LOOP
11/09/18
NO CHANGE
Target $80
LOOP
Hold
CVS Health price target raised to $80 from $70 at Loop Capital
Loop Capital analyst Andrew Wolf raised his price target on CVS Health shares to $80 from $70, citing improved sales results from CVS's core business units in Q3 and the company's maintenance of 2018 guidance. He also notes that the sector rotation into more defensive stocks has boosted the valuations of most of the other large-cap names in the group. However, Wolf keeps a Hold rating on CVS shares, noting that while its Q3 adjusted EPS of $1.73 topped consensus, it missed his own $1.78 forecast.
11/13/18
ARGS
11/13/18
NO CHANGE
Target $100
ARGS
Buy
CVS Health price target raised to $100 from $88 at Argus
Argus analyst Chris Graja raised his price target on CVS Health (CVS) to $100 and kept his Buy rating after its Q3 earnings beat, saying he remains "bullish on the management's ability to find innovative and profitable ways to reduce healthcare costs and deliver better care". The analyst also notes that he sees "significant upside for the shares if the company can close acquisition of Aetna (AET) and deliver on its financial targets". To that end, Graja cites the management's confidence expressed on the earnings call that the transaction can be closed prior to Thanksgiving and yield more than the initially estimated $750M in 2-year synergy benefits.
AET AET

10/31/18
PIPR
10/31/18
DOWNGRADE
Target $206
PIPR
Neutral
Piper downgrades Aetna to Neutral on confidence of CVS deal closing
Piper Jaffray analyst Sarah James last night downgraded Aetna (AET) to Neutral from Overweight and lowered her price target for the shares to $206 from $212. The analyst is favorable on the fundamentals of Aetna's business and is confident the CVS Health (CVS) takeover will close given the recent Department of Justice approval. She believes Aetna shares will be range bound near the $206 per share takeout price.
WCG WellCare
$246.88

-4.14 (-1.65%)

08/31/18
ARGS
08/31/18
NO CHANGE
Target $360
ARGS
Buy
WellCare price target raised to $360 from $265 at Argus
Argus analyst David Toung raised his price target on WellCare to $360 and kept his Buy rating, saying the company's acquisition of Meridian is a reflection of its "expansion mode". The analyst also raised his FY19 EPS view to $12.60 from $12.00, stating that WellCare's growth opportunities from its M&A strategy justifies its premium valuation of 24.1-times his expected forward earnings - above the peer average of 19.0-times. Toung maintains that WellCare will continue to grow through acquisitions, increased Medicare Advantage coverage, and new contract awards.
09/14/18
BMOC
09/14/18
NO CHANGE
Target $345
BMOC
Outperform
WellCare price target raised to $345 from $320 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target on WellCare to $345 to reflect the potential organic upside for FY18 EPS as well as the accretion from its Meridian acquisition in FY19-FY20. The analyst maintains his view of the deal as a "very good strategic fit" to match WellCare's expansion objectives, adding that its recent Medicaid wins in Illinois and Michigan also gives WellCare a leading market position in 6 states. Borsch kept his his Outperform rating on the shares, forecasting its core business growth rate to be sustained at over 15%.
09/17/18
CANT
09/17/18
NO CHANGE
Target $330
CANT
Overweight
WellCare price target raised to $330 from $292 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for WellCare Health Plans to $330 after incorporating the recently closed acquisition of Meridian into his 2018 estimates. The analyst now assumes high single-digit revenue growth and thinks the company's margin expansion "is quite achievable" for the near-to-mid-term. He keeps an Overweight rating on WellCare.
10/09/18
EVER
10/09/18
INITIATION
Target $365
EVER
Outperform
WellCare initiated with an Outperform at Evercore ISI
Evercore ISI initiated WellCare with an Outperform and $365 price target.

TODAY'S FREE FLY STORIES

TWTR

Twitter

$34.39

-0.01 (-0.03%)

08:12
04/23/19
04/23
08:12
04/23/19
08:12
Hot Stocks
Twitter says first priority is still 'health,' focused on proactive detection »

For products, says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

V

Visa

$160.39

0.25 (0.16%)

, MA

MasterCard

$243.00

2.02 (0.84%)

08:10
04/23/19
04/23
08:10
04/23/19
08:10
Recommendations
Visa, MasterCard analyst commentary at Morgan Stanley »

Visa, MasterCard price…

V

Visa

$160.39

0.25 (0.16%)

MA

MasterCard

$243.00

2.02 (0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 07

    May

  • 09

    May

  • 14

    May

  • 18

    May

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 11

    Jun

  • 25

    Jun

TRCB

Two River Bancorp

$15.08

(0.00%)

08:10
04/23/19
04/23
08:10
04/23/19
08:10
Earnings
Two River Bancorp reports Q1 EPS 32c, two estimates 31c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

KMB

Kimberly-Clark

$130.24

6.76 (5.47%)

08:10
04/23/19
04/23
08:10
04/23/19
08:10
Upgrade
Kimberly-Clark rating change at Argus »

Kimberly-Clark upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 06

    May

  • 29

    May

  • 23

    Jul

08:10
04/23/19
04/23
08:10
04/23/19
08:10
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

AES

AES Corp.

$17.69

-0.025 (-0.14%)

08:09
04/23/19
04/23
08:09
04/23/19
08:09
Hot Stocks
AES Corp. enters agreements to sell interests in Jordan, UK power plants »

The AES Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 13

    May

TWTR

Twitter

$34.39

-0.01 (-0.03%)

08:08
04/23/19
04/23
08:08
04/23/19
08:08
Hot Stocks
Breaking Hot Stocks news story on Twitter »

Twitter CFO says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

ADI

Analog Devices

$113.59

-1.24 (-1.08%)

08:08
04/23/19
04/23
08:08
04/23/19
08:08
Hot Stocks
Analog Devices appoints Dan Leibholz as Chief Technology Officer »

Analog Devices announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

TWTR

Twitter

$34.39

-0.01 (-0.03%)

08:08
04/23/19
04/23
08:08
04/23/19
08:08
Hot Stocks
Twitter CFO says significantly better than expected GAAP operating income in Q1 »

Comments taken from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 20

    May

ATRC

AtriCure

$27.28

0.15 (0.55%)

08:07
04/23/19
04/23
08:07
04/23/19
08:07
Hot Stocks
AtriCure enrolls first patient in DEEP IDE trial restart »

AtriCure announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 22

    May

SIEN

Sientra

$8.21

0.68 (9.03%)

08:07
04/23/19
04/23
08:07
04/23/19
08:07
Recommendations
Sientra analyst commentary at Craig-Hallum »

Craig-Hallum bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 05

    Jun

  • 13

    Nov

FELE

Franklin Electric

$51.16

-0.35 (-0.68%)

08:07
04/23/19
04/23
08:07
04/23/19
08:07
Earnings
Franklin Electric reports Q1 ex-items EPS 21c, consensus 40c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 03

    May

CACI

CACI

$187.55

1.23 (0.66%)

08:07
04/23/19
04/23
08:07
04/23/19
08:07
Hot Stocks
CACI awarded prime position on $898M multiple-award contract from U.S. Navy »

CACI International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

  • 20

    May

SPAR

Spartan Motors

$9.23

-0.35 (-3.65%)

08:06
04/23/19
04/23
08:06
04/23/19
08:06
Hot Stocks
Spartan expands partnership with Wayne Township Fire Department »

Spartan Emergency…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 22

    May

  • 28

    May

DATA

Tableau

$119.33

0.82 (0.69%)

08:06
04/23/19
04/23
08:06
04/23/19
08:06
Recommendations
Tableau analyst commentary at BMO Capital »

Tableau price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 08

    May

  • 21

    May

URGN

UroGen Pharma

$37.12

0.54 (1.48%)

, JNJ

Johnson & Johnson

$137.88

0.345 (0.25%)

08:05
04/23/19
04/23
08:05
04/23/19
08:05
Hot Stocks
UroGen Pharma announces early-stage feasibility agreement with Janssen »

UroGen Pharma (URGN)…

URGN

UroGen Pharma

$37.12

0.54 (1.48%)

JNJ

Johnson & Johnson

$137.88

0.345 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 16

    Jul

GIS

General Mills

$51.75

0.01 (0.02%)

08:05
04/23/19
04/23
08:05
04/23/19
08:05
Hot Stocks
General Mills signs 15-year power purchase agreement with Roaring Fork Wind »

General Mills signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

CAMP

CalAmp

$13.48

0.07 (0.52%)

08:05
04/23/19
04/23
08:05
04/23/19
08:05
Hot Stocks
CalAmp partners with Trophy Automotive Dealer Group »

CalAmp has partnered with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Apr

SASR

Sandy Spring Bancorp

$34.06

0.55 (1.64%)

08:04
04/23/19
04/23
08:04
04/23/19
08:04
Conference/Events
Sandy Spring Bancorp management to meet with Stephens »

Group Luncheon with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 30

    Apr

  • 13

    May

ET

Energy Transfer LP

$15.58

0.32 (2.10%)

08:03
04/23/19
04/23
08:03
04/23/19
08:03
Hot Stocks
Energy Transfer LP announces resumed operations at Mariner East 1 pipeline »

Energy Transfer LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

BOLD

Audentes Therapeutics

$39.53

0.65 (1.67%)

08:03
04/23/19
04/23
08:03
04/23/19
08:03
Hot Stocks
Audentes Therapeutics launches cGMP plasmid manufacturing facility »

Audentes Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    May

TROV

Trovagene

$3.29

-0.05 (-1.50%)

, ABBV

AbbVie

$78.10

0.54 (0.70%)

08:03
04/23/19
04/23
08:03
04/23/19
08:03
Hot Stocks
Trovagene announces preclinical data evaluating onvansertib with venetoclax »

Trovagene (TROV)…

TROV

Trovagene

$3.29

-0.05 (-1.50%)

ABBV

AbbVie

$78.10

0.54 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 28

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 18

    May

  • 31

    May

  • 05

    Jun

ABCB

Ameris Bancorp

$34.77

-0.4 (-1.14%)

, LION

Fidelity Southern

$27.79

-0.29 (-1.03%)

08:02
04/23/19
04/23
08:02
04/23/19
08:02
Hot Stocks
Ameris Bancorp sees FY19 normalized ROTCE 17%-19% »

Ameris Bancorp (ABCB)…

ABCB

Ameris Bancorp

$34.77

-0.4 (-1.14%)

LION

Fidelity Southern

$27.79

-0.29 (-1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 14

    May

NVTA

Invitae

$22.80

-0.065 (-0.28%)

, UNH

UnitedHealth

$227.14

5.4 (2.44%)

08:02
04/23/19
04/23
08:02
04/23/19
08:02
Recommendations
Invitae, UnitedHealth, NeoGenomics, LabCorp, Quest Diagnostics, Opko Health analyst commentary  »

UnitedHealth preferred…

NVTA

Invitae

$22.80

-0.065 (-0.28%)

UNH

UnitedHealth

$227.14

5.4 (2.44%)

NEO

NeoGenomics

$20.00

0.33 (1.68%)

LH

LabCorp

$144.26

-0.94 (-0.65%)

DGX

Quest Diagnostics

$85.17

-0.55 (-0.64%)

OPK

Opko Health

$2.33

-0.075 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 30

    Apr

  • 30

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 14

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 23

    Jun

  • 06

    Aug

  • 13

    Nov

FB

Facebook

$181.49

3.21 (1.80%)

08:00
04/23/19
04/23
08:00
04/23/19
08:00
Recommendations
Facebook analyst commentary at Credit Suisse »

Signs of potential value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.